Neurology
Found 10 results
Filters: Keyword is Immunologic Factors  [Clear All Filters]
2022
Perumal J, Balabanov R, Su R, Chang R, Balcer LJ, Galetta SL, Avila RL, Rutledge D, Fox RJ.  2022.  Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.. CNS Drugs. 36(9):977-993.
2021
Perumal J, Balabanov R, Su R, Chang R, Balcer L, Galetta S, Campagnolo DI, Avila R, Lee L, Rutledge D et al..  2021.  Natalizumab in Early Relapsing-Remitting Multiple Sclerosis: A 4-Year, Open-Label Study.. Adv Ther. 38(7):3724-3742.
2019
Merkies ISJ, van Schaik IN, Léger J-M, Bril V, van Geloven N, Hartung H-P, Lewis RA, Sobue G, Lawo J-P, Durn BL et al..  2019.  Efficacy and safety of IVIG in CIDP: Combined data of the PRIMA and PATH studies.. J Peripher Nerv Syst. 24(1):48-55.
Perumal J, Fox RJ, Balabanov R, Balcer LJ, Galetta S, Makh S, Santra S, Hotermans C, Lee L.  2019.  Outcomes of natalizumab treatment within 3 years of relapsing-remitting multiple sclerosis diagnosis: a prespecified 2-year interim analysis of STRIVE.. BMC Neurol. 19(1):116.
Mielke O, Bril V, Cornblath DR, Lawo J-P, van Geloven N, Hartung H-P, Lewis RA, Merkies ISJ, Sobue G, Durn B et al..  2019.  Restabilization treatment after intravenous immunoglobulin withdrawal in chronic inflammatory demyelinating polyneuropathy: Results from the pre-randomization phase of the Polyneuropathy And Treatment with Hizentra study.. J Peripher Nerv Syst. 24(1):72-79.
2018
Kocsik AS, Klein DE, Liedke M, Kaunzner UW, Nealon NM, Gauthier SA, Vartanian T, Perumal JS.  2018.  Induction of disease remission with one cycle of alemtuzumab in relapsing-remitting MS.. J Neurol. 265(5):1226-1229.
2017
Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung H-P, Hemmer B, Lublin F, Montalban X, Rammohan KW, Selmaj K et al..  2017.  Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.. N Engl J Med. 376(3):221-234.
Kaunzner UW, Kang Y, Monohan E, Kothari PJ, Nealon N, Perumal J, Vartanian T, Kuceyeski A, Vallabhajosula S, P Mozley D et al..  2017.  Reduction of PK11195 uptake observed in multiple sclerosis lesions after natalizumab initiation.. Mult Scler Relat Disord. 15:27-33.
2016
Bourre B, Gueudry J, Lefaucheur R, Borden A, Maltête D, Patel SS, Van Tassel SHaseltine, Gupta MP, Orlin A, Nealon NM.  2016.  Progressive outer retinal necrosis in a multiple sclerosis patient on natalizumab.. Neurology. 86(3):312-3.
2012
Perumal JS, Foo F, Cook P, Khan O.  2012.  Subcutaneous administration of alemtuzumab in patients with highly active multiple sclerosis.. Mult Scler. 18(8):1197-9.